APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
+0.00% today
Updated 2026-04-30
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.5M
Apellis Pharmaceuticals Inc (APLS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.20M | $14.31M | $38.18M | $27.43M | $182.13M | $203.53M | $389.24M | $960.57M | $881.76M | $760.22M | $788.73M | $885.05M |
| Cash & equivalents | $4.76M | $13.62M | $36.00M | $24.86M | $175.64M | $176.27M | $351.99M | $565.78M | $640.19M | $551.80M | $351.19M | $411.29M |
| Current assets | $5.19M | $14.25M | $38.04M | $27.37M | $182.02M | $202.44M | $373.09M | $917.19M | $824.05M | $719.52M | $766.33M | $788.95M |
| Total liabilities | $676955.00 | $1.08M | $3.20M | $3.64M | $33.19M | $42.56M | $355.02M | $756.01M | $683.10M | $590.35M | $594.21M | $656.51M |
| Current liabilities | $676955.00 | $1.08M | $3.20M | $3.64M | $6.55M | $17.02M | $65.75M | $128.33M | $131.85M | $167.61M | $247.59M | $185.51M |
| Long-term debt | — | — | — | — | $26.39M | $25.38M | $142.57M | $358.83M | $189.02M | $92.74M | $93.03M | $452.83M |
| Shareholder equity | $4.52M | $13.22M | $34.98M | $23.79M | $148.94M | $160.97M | $34.23M | $204.56M | $198.66M | $169.87M | $194.52M | $228.54M |
| Retained earnings | $-13.83M | $-24.62M | $-71.13M | $-98.26M | $-149.26M | $-276.77M | $-581.47M | $-926.35M | $-1.66B | $-2.31B | $-2.84B | $-3.04B |
| Accounts receivable | $67216.00 | $465850.00 | $1.76M | $1.35M | $1.30M | $1.47M | — | $25.00M | $80.10M | $7.73M | $206.44M | $271.72M |
| Inventory | $342743.00 | $137354.00 | — | — | — | — | — | $1.00 | $24.00M | $85.71M | $146.36M | $82.48M |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — |